Covid-19
Pfizer CEO/Chairman yet to receive COVID-19 vaccine
It will be bizarre to the world population that the Chief Executive Officer/ Chairman of a leading COVID-19 vaccine producer, Pfizer is yet to receive the vaccine jab. A video trending on tiktok relayed the Pfizer CEO, Albert Bourla, to have purportedly admitted in a media interaction that he has not received COVID-19 vaccine, though, saying that he will soon do so. The trending video relayed Bourla, who said he is 59 years old, as saying further that he is in good health and he is not a frontline worker, therefore, declaring that the COVID-19 vaccine is not recommended for his type of person.
The purported video relayed Bourla in response to a question of why he has not received a vaccine jab, saying: “soon, I can and I will. The only sensitivity here is… I don’t want to be seen as an example that I am cutting the line.
“I am 59 years old, in good health, I am not working in the frontline.
“So, my type is not recommended to get vaccination.”
Governments across the world have made covid vaccine mandatory for all citizens irrespective of infection or symptom status. However, here is CEO of one of the leading vaccine producers in the world exempting his type of people who he identified as healthy and not working in the frontline from vaccination.
-
News2 days agoFRSC opens 2026 nationwide recruitment, online applications begin July 3
-
Football7 days agoAfrica breaks World Cup record with seven teams in knockout stage
-
Entertainment4 days agoActress Cossy Ojiakor shares flooded home as heavy rainfall wreaks havoc in Lagos
-
Football1 week agoNetherlands to face Morocco, Brazil draw Japan in 2026 World Cup round of 32
-
Business1 week agoNAFDAC, FCCPC others partners OSOA Foods advocacy on food safety, MSME growth
-
Business6 days agoLogistics bottlenecks threaten Nigeria’s economic growth, industry leaders warn
-
Business6 days agoInflation, high interest rates loom as FG credit hits N40.38tn
-
Business1 week agoLagos leads as States receive N2.49tn FAAC allocation in Q1 2026

